Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

US FDA Approval Of Valeant’s Siliq Comes With REMS, Boxed Warning

Executive Summary

Measures are aimed at mitigating risk of suicidal ideation and behavior with the psoriasis drug, but company will not have to conduct a postmarketing registry to evaluate this risk.


Related Content

Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review
Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar
FDA's NDA And BLA Approvals: Siliq
Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
Post-Marketing Registry, Suicidality Warning Could Be Paradox For Siliq
Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry


Related Companies